Abstract
A sensitive, rapid, reverse phase and isocratic high-performance liquid chromatography (HPLC) method has been developed for the estimation of telmisartan in human plasma. Sample detection was carried out at 297 nm using an Ultraviolet (UV)-PDA detector. Plasma sample pretreatment consist of protein precipitation extraction with methanol. The compounds were separated using a mobile phase of sodium dihydrogen phosphate buffer (pH 3.0): acetonitrile (ACN) (42:58, v/v) on a Phenomenex LUNA C18, column (250x4.6 mm i.d., 5μm) at a flow rate of 1.2 ml/min. The total run time for the assay was 4.2 min. The method was validated over the range of 40–1600 ng/ml. The lowest limit of quantification and limit of detection was found 40 and 2.8 ng/ml respectively. The recovery for low, medium and high quality control samples were found 81.13, 79.96 & 82.40 % respectively. The method was found to be accurate and precise. Stability data of analytes revealed that they are stable in plasma under different stability conditions. The results observed conclude that the developed method is very appropriate and applicable for antihypertensive research programs of telmisartan.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
